Sijbrand Hofker.

Schaapherder, M.D., Ph.D., Casper H. Van Eijck, M.D., Ph.D., Thomas L. Bollen, M.D., Bert van Ramshorst, M.D., Ph.D., Vincent B. Nieuwenhuijs, M.D., Ph.D., Robin Timmer, M.D., Ph.D., Johan S.D., Ph.D., Philip M. Kruyt, M.D., Eric R. Manusama, M.D., Ph.D., Erwin van der Harst, M.D., Ph.D., George P. Van der Schelling, M.D., Ph.D., Tom Karsten, M.D., Ph.D., Eric J. Hesselink, M.D., Ph.D., Cornelis J. Van Laarhoven, M.D., Ph.D., Camiel Rosman, M.D., Ph.D., Koop Bosscha, M.D., Ph.D., Ralph J. De Wit, M.D., Ph.D., Alexander P. Houdijk, M.D., Ph.D., Maarten S. Van Leeuwen, M.D., Ph.D., Erik Buskens, M.D., Ph.D., and Hein G.The spectral range of infecting bacteria was similar in both groupings, with Escherichia coli defined as the causative bacterium in 30 of 36 patients in the antibiotic group and in 46 of 55 patients in the placebo group., and Table 1 in the Supplementary Appendix, available with the entire text of this article at NEJM.org).). Through the study period, urinary system infection with fever developed in 19 of 288 individuals in the antibiotic group and in 36 of 288 patients in the placebo group , a notable difference of 6 %age points with Fever .). The progression of abnormal results on renal scanning from baseline to follow-up did not differ significantly between your antibiotic group and the placebo group, although, as expected, hardly any patients had a worsening of scanning results at 12 months, in comparison with baseline.